However, the differences in CCL5 and CCL4 expression between IL-32–treated tumors from WT and Batf3–/– mice were not statistically significant (Figure 5, F and G), suggesting that DC are not exclusively responsible for the increased tumor chemokine levels in response to IL-32 treatment. The gene discussed is CCL4; the disease is neoplasm.